Celsion Doses First Ovarian Cancer Patient in Phase 1/2 Trial of GEN-1

Celsion Doses First Ovarian Cancer Patient in Phase 1/2 Trial of GEN-1
The Phase 1/2 trial evaluating Celsion’s investigational DNA-based immunotherapy GEN-1 as an add-on to standard chemotherapy for localized treatment of ovarian cancer has started dosing patients. GEN-1 is a nanoparticle containing the DNA sequence for the pro-inflammatory protein interleukin-12 (IL-12). When delivered to the tumor, GEN-1 induces a sustained production and release of IL-12, triggering an immune response against the tumor cells. “We are very excited to advance our ovarian cancer research, the foundation of which is based on a known anti-cancer agent, IL-12. Over the past three decades, IL-12 has convincingly demonstrated its capability to actively recruit the body's immune system to work against cancers. However, its clinical promise has been limited by a poor safety profile. GEN-1 has the potential to address this,” Michael H. Tardugno, Celsion's chairman, president and chief executive office, said in a press release. “In our novel, gene-mediated formulation, we believe GEN-1 has the potential to effectively harness IL-12’s antitumor activity for cancer patients with a dimension of safety not found in the free, recombinant form,” he added. The OVATION II study (NCT03393884),
Subscribe or to access all post and page content.